Allogenic Islet Cell Transplantation

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Diabetes Mellitus, Type 1
Interventions
DRUG

Allogenic islet cells (human, U. Chicago)

Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

PROCEDURE

Intraportal infusion of islet cells

Intraportal infusion of islet cell through the portal vein in the liver.

Trial Locations (1)

60637

The University of Chicago Hospitals, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER

NCT00160732 - Allogenic Islet Cell Transplantation | Biotech Hunter | Biotech Hunter